Amarin study links elevated lipoprotein(a) to residual cardiovascular risk despite statin therapy
AMRN•An analysis of REDUCE-IT linked lipoprotein(a) to residual cardiovascular risk despite statin-controlled cholesterol, while other apoB-containing lipoproteins did not predict risk.
1. Study findings
Amarin highlighted cardiovascular research presented at the American Heart Association Scientific Sessions 2026. The REDUCE-IT analysis linked lipoprotein(a) to residual cardiovascular risk despite statin-controlled cholesterol; other apoB-containing lipoproteins did not predict risk.
